# vTv Therapeutics Inc.: financial statements, quarterly

VTVT · Nasdaq · CIK 1641489 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vtvt.md) · [Financials](/companies/vtvt/financials.md) · [Filings](/companies/vtvt/filings.md) · [Insiders](/companies/vtvt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vtvt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001641489-24-000075.md) | [0.0 d](/filings/0001641489-26-000010.md) | [1.0](/filings/0001641489-25-000026.md) | [0.0](/filings/0001641489-25-000053.md) | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [0.0](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [36.8](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) |
| Research and development | $m | [2.8](/filings/0001641489-24-000075.md) | [2.1 d](/filings/0001641489-26-000010.md) | [2.6](/filings/0001641489-25-000026.md) | [3.4](/filings/0001641489-25-000053.md) | [3.2](/filings/0001641489-25-000060.md) | [2.2 d](/filings/0001641489-26-000010.md) | [2.8](/filings/0001641489-26-000020.md) | [4.1](/filings/0001641489-26-000030.md) | [7.0](/filings/0001641489-25-000060.md) | [3.9 d](/filings/0001641489-26-000010.md) | [9.0](/filings/0001641489-26-000020.md) | [8.8](/filings/0001641489-26-000030.md) |
| Operating income | $m | [(5.4)](/filings/0001641489-24-000075.md) | [(4.7) d](/filings/0001641489-26-000010.md) | [(5.6)](/filings/0001641489-25-000026.md) | [(7.2)](/filings/0001641489-25-000053.md) | [(6.5)](/filings/0001641489-25-000060.md) | [(4.9) d](/filings/0001641489-26-000010.md) | [(6.5)](/filings/0001641489-26-000020.md) | [(7.7)](/filings/0001641489-26-000030.md) | [(10.7)](/filings/0001641489-25-000060.md) | [(7.9) d](/filings/0001641489-26-000010.md) | [23.3](/filings/0001641489-26-000020.md) | [(13.9)](/filings/0001641489-26-000030.md) |
| Interest expense | $m | [0.0](/filings/0001641489-23-000070.md) | [0.0 d](/filings/0001641489-24-000012.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001641489-24-000075.md) | [0.0 d](/filings/0001641489-26-000010.md) | [0.1](/filings/0001641489-25-000026.md) | [0.0](/filings/0001641489-25-000053.md) | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [0.0](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) | [0.0](/filings/0001641489-25-000060.md) | [0.0 d](/filings/0001641489-26-000010.md) | [0.0](/filings/0001641489-26-000020.md) | [0.0](/filings/0001641489-26-000030.md) |
| Net income | $m | [(6.7)](/filings/0001641489-24-000075.md) | [(3.5) d](/filings/0001641489-26-000010.md) | [(4.9)](/filings/0001641489-25-000026.md) | [(5.2)](/filings/0001641489-25-000053.md) | [(4.8)](/filings/0001641489-25-000060.md) | [(3.6) d](/filings/0001641489-26-000010.md) | [(5.1)](/filings/0001641489-26-000020.md) | [(6.0)](/filings/0001641489-26-000030.md) | [(8.7)](/filings/0001641489-25-000060.md) | [(7.1) d](/filings/0001641489-26-000010.md) | [24.1](/filings/0001641489-26-000020.md) | [(13.1)](/filings/0001641489-26-000030.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.2](/filings/0001641489-23-000070.md) | [9.4](/filings/0001641489-25-000014.md) | [52.3](/filings/0001641489-24-000029.md) | [45.5](/filings/0001641489-24-000061.md) | [41.6](/filings/0001641489-24-000075.md) | [36.7](/filings/0001641489-26-000010.md) | [31.1](/filings/0001641489-25-000026.md) | [25.9](/filings/0001641489-25-000053.md) | [98.5](/filings/0001641489-25-000060.md) | [88.9](/filings/0001641489-26-000030.md) | [98.1](/filings/0001641489-26-000020.md) | [86.6](/filings/0001641489-26-000030.md) |
| Current assets | $m | [10.1](/filings/0001641489-23-000070.md) | [10.7](/filings/0001641489-25-000014.md) | [53.9](/filings/0001641489-24-000029.md) | [46.2](/filings/0001641489-24-000061.md) | [43.0](/filings/0001641489-24-000075.md) | [38.1](/filings/0001641489-26-000010.md) | [31.9](/filings/0001641489-25-000026.md) | [26.4](/filings/0001641489-25-000053.md) | [99.5](/filings/0001641489-25-000060.md) | [89.9](/filings/0001641489-26-000030.md) | [98.8](/filings/0001641489-26-000020.md) | [87.6](/filings/0001641489-26-000030.md) |
| Total assets | $m | [14.9](/filings/0001641489-23-000070.md) | [11.0](/filings/0001641489-25-000014.md) | [54.2](/filings/0001641489-24-000029.md) | [46.5](/filings/0001641489-24-000061.md) | [43.2](/filings/0001641489-24-000075.md) | [38.3](/filings/0001641489-26-000010.md) | [32.0](/filings/0001641489-25-000026.md) | [26.4](/filings/0001641489-25-000053.md) | [99.5](/filings/0001641489-25-000060.md) | [89.9](/filings/0001641489-26-000030.md) | [98.8](/filings/0001641489-26-000020.md) | [87.6](/filings/0001641489-26-000030.md) |
| Current liabilities | $m | [10.3](/filings/0001641489-23-000070.md) | [10.6](/filings/0001641489-25-000014.md) | [8.9](/filings/0001641489-24-000029.md) | [7.0](/filings/0001641489-24-000061.md) | [6.4](/filings/0001641489-24-000075.md) | [5.2](/filings/0001641489-26-000010.md) | [4.3](/filings/0001641489-25-000026.md) | [5.3](/filings/0001641489-25-000053.md) | [10.2](/filings/0001641489-25-000060.md) | [6.6](/filings/0001641489-26-000030.md) | [6.9](/filings/0001641489-26-000020.md) | [7.0](/filings/0001641489-26-000030.md) |
| Total liabilities | $m | [29.4](/filings/0001641489-23-000070.md) | [29.6](/filings/0001641489-25-000014.md) | [28.2](/filings/0001641489-24-000029.md) | [26.0](/filings/0001641489-24-000061.md) | [25.3](/filings/0001641489-24-000075.md) | [24.0](/filings/0001641489-26-000010.md) | [23.1](/filings/0001641489-25-000026.md) | [24.0](/filings/0001641489-25-000053.md) | [29.0](/filings/0001641489-25-000060.md) | [25.5](/filings/0001641489-26-000030.md) | [8.9](/filings/0001641489-26-000020.md) | [9.0](/filings/0001641489-26-000030.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(25.2)](/filings/0001641489-23-000070.md) | [(24.7)](/filings/0001641489-25-000014.md) | [20.8](/filings/0001641489-24-000029.md) | [16.5](/filings/0001641489-24-000061.md) | [15.0](/filings/0001641489-24-000075.md) | [12.2](/filings/0001641489-26-000010.md) | [7.9](/filings/0001641489-25-000026.md) | [2.8](/filings/0001641489-25-000053.md) | [70.5](/filings/0001641489-25-000060.md) | [64.4](/filings/0001641489-26-000030.md) | [90.0](/filings/0001641489-26-000020.md) | [78.6](/filings/0001641489-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.8) d](/filings/0001641489-24-000075.md) | [(2.9) d](/filings/0001641489-26-000010.md) | [(7.3)](/filings/0001641489-25-000026.md) | [(6.7) d](/filings/0001641489-25-000053.md) | [(6.4) d](/filings/0001641489-25-000060.md) | [(4.8) d](/filings/0001641489-26-000010.md) | [(5.7)](/filings/0001641489-26-000020.md) | [(5.1) d](/filings/0001641489-26-000030.md) | [(5.2) d](/filings/0001641489-25-000060.md) | [(9.3) d](/filings/0001641489-26-000010.md) | [9.2](/filings/0001641489-26-000020.md) | [(11.4) d](/filings/0001641489-26-000030.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001641489-23-000070.md) | [0.0 d](/filings/0001641489-25-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.